Posted On: 08/12/2013 3:26:12 AM
Post# of 72437
“Due to the Company’s strong financial backing from our $10 million equity line from Aspire Capital, and further progress in our clinical trials, we are intending to move to a senior exchange,” commented Leo Ehrlich, CEO.
I take it the further progress in our clinical trials is somewhere between good and out-of-this-world fantastic. Anything less would make an intention to up-list unfounded. Sounds good to me!
I take it the further progress in our clinical trials is somewhere between good and out-of-this-world fantastic. Anything less would make an intention to up-list unfounded. Sounds good to me!
![](/m/images/icons/icon_smile.gif)
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)